Biosynthesis of C-nucleoside antibiotics in actinobacteria: recent advances and future developments

Microb Cell Fact. 2022 Jan 4;21(1):2. doi: 10.1186/s12934-021-01722-z.

Abstract

Epidemic diseases and antibiotic resistance are urgent threats to global health, and human is confronted with an unprecedented dilemma to conquer them by expediting development of new natural product related drugs. C-nucleoside antibiotics, a remarkable group of microbial natural products with diverse biological activities, feature a heterocycle base linked with a ribosyl moiety via an unusual C-glycosidic bond, and have played significant roles in healthcare and for plant protection. Elucidating how nature biosynthesizes such a group of antibiotics has provided the basis for engineered biosynthesis as well as targeted genome mining of more C-nucleoside antibiotics towards improved properties. In this review, we mainly summarize the recent advances on the biosynthesis of C-nucleoside antibiotics, and we also tentatively discuss the future developments on rationally accessing C-nucleoside diversities in a more efficient and economical way via synthetic biology strategies.

Keywords: Biosynthesis; C-nucleoside antibiotics; Genome mining; Natural product; Synthetic biology.

Publication types

  • Review

MeSH terms

  • Actinobacteria / genetics
  • Actinobacteria / metabolism*
  • Anti-Bacterial Agents / biosynthesis*
  • Biological Products / chemistry
  • Nucleosides / biosynthesis*
  • Streptomyces / genetics
  • Streptomyces / metabolism
  • Synthetic Biology / methods*
  • Synthetic Biology / trends

Substances

  • Anti-Bacterial Agents
  • Biological Products
  • Nucleosides